Overview

A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

The primary purpose is to demonstrate the bioequivalence of naproxen administered as VIMOVO manufactured at a new facility in Sweden (AstraZeneca) to that of naproxen administered as VIMOVO manufactured in the USA (Patheon) and to a marketed enteric-coated naproxen formulation.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Esomeprazole
Naproxen